Patient benefit rate and guarantee time bias in analysis of outcomes for gynecologic oncology patients receiving targeted treatment after somatic tumor genetic testing.
作者信息
Cathcart Ann M, Chen Emerson Y, Bruegl Amanda
机构信息
Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA.
Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
出版信息
Gynecol Oncol Rep. 2022 Jun 9;42:101019. doi: 10.1016/j.gore.2022.101019. eCollection 2022 Aug.
Abstract
摘要
相似文献
1
Patient benefit rate and guarantee time bias in analysis of outcomes for gynecologic oncology patients receiving targeted treatment after somatic tumor genetic testing.
Gynecol Oncol Rep. 2022 Jun 9;42:101019. doi: 10.1016/j.gore.2022.101019. eCollection 2022 Aug.
2
Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
Gynecol Oncol. 2021 Nov;163(2):220-228. doi: 10.1016/j.ygyno.2021.08.027. Epub 2021 Sep 9.
3
Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - A systematic review and meta-analysis.
Gynecol Oncol. 2021 Apr;161(1):46-55. doi: 10.1016/j.ygyno.2020.12.035. Epub 2020 Dec 30.
4
Perioperative Laboratory Abnormalities in Gynecologic Oncology Surgical Patients.
J Gynecol Surg. 2016 Apr 1;32(2):111-118. doi: 10.1089/gyn.2015.0106.
5
Germline and Somatic Tumor Testing in Gynecologic Cancer Care.
Obstet Gynecol Clin North Am. 2019 Mar;46(1):37-53. doi: 10.1016/j.ogc.2018.09.003.
6
Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.
Gynecol Oncol. 2017 Aug;146(2):217-224. doi: 10.1016/j.ygyno.2017.06.002. Epub 2017 Jun 7.
7
Applying Artificial Intelligence to Gynecologic Oncology: A Review.
Obstet Gynecol Surv. 2021 May;76(5):292-301. doi: 10.1097/OGX.0000000000000902.
8
Implicit bias toward cervical cancer: Provider and training differences.
Gynecol Oncol. 2019 Apr;153(1):80-86. doi: 10.1016/j.ygyno.2019.01.013. Epub 2019 Feb 8.
9
Thirty-day outcomes after gynecologic oncology surgery: A single-center experience of enhanced recovery after surgery pathways.
Acta Obstet Gynecol Scand. 2021 Feb;100(2):353-361. doi: 10.1111/aogs.14009. Epub 2020 Oct 16.
10
Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Int J Gynecol Cancer. 2016 Jun;26(5):892-7. doi: 10.1097/IGC.0000000000000689.
本文引用的文献
1
Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls.
Gynecol Oncol. 2021 Nov;163(2):217-219. doi: 10.1016/j.ygyno.2021.10.005.
2
Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
Gynecol Oncol. 2021 Nov;163(2):220-228. doi: 10.1016/j.ygyno.2021.08.027. Epub 2021 Sep 9.
3
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020.
Ann Oncol. 2021 Jul;32(7):926-932. doi: 10.1016/j.annonc.2021.04.003. Epub 2021 Apr 20.
4
Immortal Time Bias in National Cancer Database Studies.
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):5-12. doi: 10.1016/j.ijrobp.2019.07.056. Epub 2019 Aug 9.
5
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
JAMA Oncol. 2018 Aug 1;4(8):1093-1098. doi: 10.1001/jamaoncol.2018.1660.
6
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol. 2016 Apr;141(1):43-8. doi: 10.1016/j.ygyno.2016.02.025.
7
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
J Clin Oncol. 2015 Mar 10;33(8):930-6. doi: 10.1200/JCO.2014.58.3401. Epub 2015 Jan 26.
8
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Gynecol Oncol. 2014 Mar;132(3):585-92. doi: 10.1016/j.ygyno.2014.01.015. Epub 2014 Jan 20.
9
Challenges of guarantee-time bias.
J Clin Oncol. 2013 Aug 10;31(23):2963-9. doi: 10.1200/JCO.2013.49.5283. Epub 2013 Jul 8.
10
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
Br J Cancer. 2013 May 14;108(9):1771-7. doi: 10.1038/bjc.2013.183. Epub 2013 Apr 23.
Zotero 插件